TARS - Company ID 0001819790
The table below shows Tarsus Pharmaceuticals, Inc.'s balance sheet by quarter, as reported in the company's quarterly filings. All figures are in US dollars; negative values appear in red.
| Line item | Q1 2026 | Q3 2025 | Q2 2025 | Q1 2025 | Q3 2024 | Q2 2024 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $102.19M | $112.72M | $96.65M | $175.79M | $176.21M | $181.09M |
| Short-term investments | $286.54M | $289.11M | $284.50M | $232.13M | $140.74M | $142.49M |
| Receivables | $100.34M | $72.62M | $58.33M | $62.43M | $29.16M | $29.53M |
| Inventory | $4.57M | $3.84M | $3.87M | $2.71M | $2.85M | $2.19M |
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| Total current assets |
| $537.23M |
| $501.70M |
| $474.43M |
| $480.77M |
| $357.12M |
| $362.59M |
| Property, plant & equipment | $17.67M | $5.75M | $3.18M | $2.79M | $2.39M | $2.24M |
| Goodwill | - | - | - | - | - | - |
| Total assets | $581.13M | $534.56M | $494.99M | $500.75M | $376.30M | $376.84M |
| Accounts payable | $24.13M | - | - | - | - | - |
| Total current liabilities | $143.51M | $117.05M | $90.25M | $86.31M | $65.87M | $51.57M |
| Long-term debt | $72.60M | $72.28M | $72.13M | $71.98M | $71.71M | $71.58M |
| Total liabilities | $232.18M | $199.48M | $162.38M | $158.29M | $138.82M | $124.60M |
| Retained earnings | -$433.60M | -$418.25M | -$405.67M | -$385.33M | -$337.10M | -$313.68M |
| Total equity | $348.95M | $335.08M | $332.61M | $342.46M | $237.48M | $252.25M |